



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

ASSISTANT SECRETARY
AND COMMISSIONER

Food and Drug Administration
Rockville MD 20857

98 JUL -7 PM 3:24

U.S. PATENT
AND
TRADEMARK OFFICE

Re: PANDEL Cream
Docket No.: 97E-0271

JUN 23 1998

The Honorable Bruce Lehman
Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, DC 20231

Dear Commissioner Lehman:

This is in regard to the application for patent term extension for U.S. Patent No. 4,290,962, filed by Taisho Pharmaceutical Co. Ltd, under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for PANDEL Cream, the human drug product claimed by the patent.

The total length of the regulatory review period for PANDEL Cream is 4,165 days. Of this time, 3,078 days occurred during the testing phase and 1,087 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(j) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: October 6, 1985.

FDA has verified the applicant's claim that the date the Investigational New Drug application became effective was on October 6, 1985.

2. The date the application was initially submitted with respect to the human drug product under section 505 of the Federal Food, Drug, and Cosmetic Act: March 10, 1994.

The applicant claims March 1, 1994, as the date the New Drug Application (NDA) for PANDEL Cream (NDA 20-453) was initially submitted. However, FDA records indicate that NDA 20-453 was submitted on March 10, 1994.


3. The date the application was approved: February 28, 1997.

FDA has verified the applicant's claim that NDA 20-453 was approved on February 28, 1997.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,



Thomas J. McGinnis, R.Ph.
Deputy Associate Commissioner
for Health Affairs

cc: Paul E. White, Jr.
Pillsbury Madison & Sutro, LLP
Cushman Darby & Cushman, Intell. Prop Gr
1100 New York Ave, NW
Washington, DC 20005-3918